Q-omics provides the consensus-scored RTP2 profile across patient tissues and cancer cell-line models. RTP2 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RTP2 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, RTP2 RNA expression shows 6,448 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, and STAD as cancer lineages where RTP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RTP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RTP2 survival associations across molecular data types. RTP2 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RTP2 RNA expression–survival associations across cancer types. High RTP2 expression shows unfavorable associations in SCLC, but favorable associations in KIRC, ACC, MESO, LUSC and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RTP2 RNA expression.
This table summarizes RTP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RTP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RTP2 shows lower tumor expression in THCA and higher tumor expression in KIRC, LIHC, KICH, BRCA and COAD. The KIRC box plot shows higher RTP2 RNA expression in tumor versus normal tissue (log2 FC = +0.693, t-test p < 0.001).
This table shows molecular features associated with RTP2 in patient tissues and cancer cell lines. In patient samples, RTP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RTP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
